varespladib

11/11/2022 - "To date, twenty-nine clinical studies evaluating the safety, pharmacokinetics (PK), and efficacy of varespladib for non-snakebite envenoming conditions have been completed in more than 4600 human subjects, and the drugs were generally well-tolerated and considered safe for use in humans. "
11/11/2022 - "Since 2016, more than 30 publications describing the structure, function, and efficacy of varespladib have directly addressed its potential for the treatment of snakebite. "
11/11/2022 - "This review summarizes preclinical findings and outlines the scientific support, the potential limitations, and the next steps in the development of varespladib's use as a snakebite treatment, which is now in Phase 2 human clinical trials in the United States and India."
11/11/2022 - "Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes."
12/28/2022 - "Extensive preclinical data support clinical evaluation of varespladib as a treatment for snakebite envenoming (SBE). "

05/01/2012 - "The authors investigate varespladib ex vivo efficacy in different forms of neonatal lung injury. "
05/01/2012 - "Varespladib was able to inhibit sPLA2 in the types of neonatal lung injury investigated. "
05/01/2012 - "Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury."
04/01/2001 - "Treatment with S-5920/LY315920Na 1 hr after OA infusion, but not 2 hrs after infusion, significantly attenuated the lung injury, as estimated by hypoxemia, decreased lung compliance, pulmonary edema, and vascular permeability. "
10/01/1999 - "Pretreatment with S-5920/LY315920Na diminished the OA-induced PLA(2) activity in the BALF and dose-dependently attenuated the previously described lung injury induced by OA, accompanied by protection against lung surfactant degradation and production of thromboxane A(2) (TXA(2)) and leukotriene B(4) (LTB(4)). "

01/01/2013 - "Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury. "
04/01/2001 - "We attempted to determine whether group IIA secretory phospholipase A2 (sPLA2-IIA) blockade after the onset of lung injury exerted therapeutic efficacy in the treatment of oleic acid (OA)-induced acute lung injury by using S-5920/LY315920Na, a novel specific inhibitor of sPLA2-IIA, with special interest in the changes of lung surfactant. "

03/01/2003 - "However, prospectively planned secondary analyses suggested that treatment with LY315920Na/S-5920 was associated with an improvement in survival in patients treated within 18 hrs of the first sepsis-induced organ failure."
08/01/2005 - "In a previous study, a selective inhibitor of sPLA2-IIA (LY315920NA/S-5920) was well tolerated and appeared to improve survival in a subgroup of patients who received the drug within 24 hrs of first sepsis-induced organ failure. "
03/01/2003 - "The primary objectives of this study were to determine whether there was a dose-response relationship between two doses of LY315920Na/S-5920 compared with placebo in the reduction of 28-day all-cause mortality in patients with severe sepsis and to determine whether LY315920Na/S-5920 had an acceptable safety profile.(2) (2) (2) Multicenter, double-blind, placebo-controlled trial of two doses of LY315920Na/S-5920 in a parallel design. "
08/01/2005 - "Multicenter, double-blind, placebo-controlled, parallel-group clinical trial of LY315920NA/S-5920 in patients with severe sepsis. "
03/01/2003 - "Administration of LY315920Na/S-5920 had an acceptable safety profile in patients with severe sepsis. "

03/01/2022 - "This study investigated the efficacy of varespladib, a small molecule PLA2 (phospholipase A2) inhibitor, given as a bolus subcutaneously upon the onset of krait venom-induced paralysis in a mouse experimental envenoming and rescue model, where the severity of neurotoxicity was scored and the survival rate was monitored over 24 h. "